Type 2 Diabetes

A subgroup analysis from DAPA-HF show the SGLT2 inhibitor provided efficacy regardless of HFrEF patient gender.

Patients who continued taking semaglutide (Rybelsus/Novo Nordisk) after an initial 20-week therapy period saw continued weight loss, leading to the hope that a new pharmacologic approach to weight loss could be on the horizon.

A phase 2 trial examining the effects of daily semaglutide over a 72-week period suggests the GLP1-RA could help patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) achieve NASH resolution.

An analysis of the CHAMP-HF registry indicates KCCQ-OS was more sensitive at tracking changes in disease state among heart failure patients, indicating the importance of including patient-reported outcome measures in heart failure management.

An expert physician in cardiology and metabolic management walks through a presentation on identifying, addressing, and continually treating for heightened cardiometabolic risk.

Juan Frias, MD, breaks down results of a post-hoc analysis of the AWARD-11 study examining expanded doses of dulaglutide according to baseline HbA1c levels.

Continuing treatment results in a nearly 8% reduction in weight during a 48 week period.

The therapy could offer a therapeutic option with a better safety profile, investigators said.

Learn more about once-weekly basal insulin Fc from Eli Lilly and Company in this interview with the lead investigator from their phase 2 trial, which was presented at ENDO 2021.

The approval is based on results from Phase 3 trials showing high efficacy in adult and pediatric populations.

Zealand Pharma announced the US FDA approved dasiglucagon (Zegalogue) for treatment of severe hypoglycemia in patients with diabetes aged 6 and older and the injectable will be available as both an auto injector and a prefilled syringe.

A literature review of studies assessing SGLT2 inhibitor use in kidney transplant patients with diabetes suggests use did not impact graft function and was associated with improvements in glucose control and body weight.

A single-injection co-formulation of pramlitide and insulin may be a better alternative to separate administrations of both key treatments in adults with T1D, particularly following meals.

A majority of surveyed patients and providers want to continue telemedicine follow-up visits after the pandemic ends.

Stimulating steroid receptor co-activators may play a role in repairing heart tissue following severe myocardial infarction.

Many patients with genetic obesity disorder experience resistance to treatment, including intensive lifestyle therapy.

Evening and late-night preferences of women with GDM is linked to a significantly greater risk of preeclampsia and NICU treatment.

A post-hoc analysis of the AWARD-11 trial indicates that 4.5 mg of dulaglutide was effective in lowering and maintaining A1C levels <7% regardless of baseline levels.

A review of observational data suggests the presence of type 2 diabetes could increase risk of developing Parkinson disease and might also speed the progression of motor symptoms.

A trial of more than 20k women from investigators at Kaiser Permanente found there were no significant differences in outcomes among pregnant women undergoing gestational diabetes screenings using the ADA's 1-step approach versus the ACOG's 2-step approach.

Check out the Endocrine Outlook podcast, brought to you by the Endocrinology Network. This episode focuses on semaglutide 1 mg as a weight loss therapy for patients who are obese or overweight.

Compared with a two-step screening method, a one-step approach is associated with more diagnosed incidences of gestational diabetes, despite a lower adherence rate.

Our latest case report from Brady Pregerson, MD, features a woman in her 70s presenting with a facial droop and slurred speech. Can you help determine the correct diagnosis?

Principal investigator of the SURPASS-2 trial discusses the results of the trial and how it informs clinicians on the use of tirzepatide versus currently approved diabetes medications.